Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2015

01.07.2015

Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor

verfasst von: Alon Eisen, Hila Lerman-Shivek, Leor Perl, Eldad Rechavia, Dorit Leshem-Lev, Noa Zemer-Wassercug, Oshrat Dadush, Shirit Kazum, Pablo Codner, Ran Kornowski, Eli I. Lev

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Reticulated platelets (RP) are young, hyperactive platelets that are increased during situations of enhanced platelet turnover such as acute myocardial infarction (AMI). The dynamics of RP levels after AMI is not established. We aimed to characterize the levels of circulating RP over time in patients with AMI. Patients with AMI treated with ticagrelor or prasugrel who underwent percutaneous coronary intervention (PCI) were tested for circulating RP using flow cytometry with Thiazole orange staining at 3 time points at 2–4 days, 30–60 days and 1 year post PCI. Platelet reactivity was assessed using the VerifyNow P2Y12 assay at these time points (results in platelet reactivity units—PRU). Thirty-five patients were included in the study (mean age 62.6 ± 9.1 years, 82.9 % males). Median RP levels were similar at the first and second time points (17.5 %, IQR 25–75: 10.8–22.4 % and 14.9 %, IQR 25–75: 9.7–26.8 %, respectively; p = 0.75). However, RP levels after 1 year were significantly lower as compared to the first and second time points (10.5 % (IQR 25–75: 5.3–18.1 %), p = 0.005 and p = 0.01, respectively). Residual platelet reactivity was very low at all 3 time points (median PRU 25, IQR 25–75: 7–53) and did not change significantly between them (p = 0.66). No significant correlation was found between levels of RP and PRU at any given time point. RP levels of patients with AMI treated with prasugrel or ticagrelor decrease over time after the acute event. However, RP levels over time do not correlate well with residual platelet reactivity.
Literatur
1.
Zurück zum Zitat Campo G, Parrinello G, Ferraresi P et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57(25):2474–2483CrossRefPubMed Campo G, Parrinello G, Ferraresi P et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57(25):2474–2483CrossRefPubMed
2.
Zurück zum Zitat Codner P, Vaduganathan M, Rechavia E et al (2012) Clopidogrel response up to six months after acute myocardial infarction. Am J Cardiol 110(3):321–325CrossRefPubMed Codner P, Vaduganathan M, Rechavia E et al (2012) Clopidogrel response up to six months after acute myocardial infarction. Am J Cardiol 110(3):321–325CrossRefPubMed
3.
Zurück zum Zitat Scalone G, Coviello I, Barone L et al (2011 Aug) Evidence of increased platelet reactivity in the first six months after acute ST segment elevation myocardial infarction. Thromb Res 128(2):174–178CrossRefPubMed Scalone G, Coviello I, Barone L et al (2011 Aug) Evidence of increased platelet reactivity in the first six months after acute ST segment elevation myocardial infarction. Thromb Res 128(2):174–178CrossRefPubMed
4.
Zurück zum Zitat Price MJ, Angiolillo DJ, Teirstein PS et al (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 124:1132–1137CrossRefPubMed Price MJ, Angiolillo DJ, Teirstein PS et al (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 124:1132–1137CrossRefPubMed
5.
Zurück zum Zitat Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:2553–2560CrossRefPubMed Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:2553–2560CrossRefPubMed
6.
Zurück zum Zitat Bonello L, Pansieri M, Mancini J et al (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58:467–473CrossRefPubMed Bonello L, Pansieri M, Mancini J et al (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58:467–473CrossRefPubMed
7.
Zurück zum Zitat Parodi G, Marcucci R, Valenti R et al (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306:1215–1223CrossRefPubMed Parodi G, Marcucci R, Valenti R et al (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306:1215–1223CrossRefPubMed
8.
Zurück zum Zitat Aradi D, Komócsi A, Vorobcsuk A et al (2010 Sep) Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 160(3):543–551CrossRefPubMed Aradi D, Komócsi A, Vorobcsuk A et al (2010 Sep) Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 160(3):543–551CrossRefPubMed
9.
Zurück zum Zitat Michelson AD, Frelinger AL 3rd, Braunwald E et al (2009) Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 30:1753–1763CrossRefPubMed Michelson AD, Frelinger AL 3rd, Braunwald E et al (2009) Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 30:1753–1763CrossRefPubMed
10.
Zurück zum Zitat Storey RF, Angiolillo DJ, Patil SB et al (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56:1456–1462CrossRefPubMed Storey RF, Angiolillo DJ, Patil SB et al (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56:1456–1462CrossRefPubMed
11.
Zurück zum Zitat Perl L, Lerman-Shivek H, Rechavia E et al (2014) Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 63(6):513–517CrossRefPubMed Perl L, Lerman-Shivek H, Rechavia E et al (2014) Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 63(6):513–517CrossRefPubMed
12.
Zurück zum Zitat Alexopoulos D, Xanthopoulou I, Siapika A et al (2013) Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients. Int J Cardiol 168(1):629–630CrossRefPubMed Alexopoulos D, Xanthopoulou I, Siapika A et al (2013) Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients. Int J Cardiol 168(1):629–630CrossRefPubMed
13.
Zurück zum Zitat Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577–2585CrossRefPubMed Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577–2585CrossRefPubMed
14.
Zurück zum Zitat Robinson MS, Mackie IJ, Khair K et al (1998) Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes. Br J Haematol 100:351–357CrossRefPubMed Robinson MS, Mackie IJ, Khair K et al (1998) Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes. Br J Haematol 100:351–357CrossRefPubMed
15.
Zurück zum Zitat Lakkis N, Dokainish H, Abuzahra M et al (2004) Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 44:2091–2093CrossRefPubMed Lakkis N, Dokainish H, Abuzahra M et al (2004) Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 44:2091–2093CrossRefPubMed
16.
Zurück zum Zitat McCabe DJ, Harrison P, Sidhu PS, Brown MM, Machin SJ (2004) Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 126:861–869CrossRefPubMed McCabe DJ, Harrison P, Sidhu PS, Brown MM, Machin SJ (2004) Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 126:861–869CrossRefPubMed
17.
Zurück zum Zitat Guthikonda S, Alviar CL, Vaduganathan M et al (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52:743–749CrossRefPubMed Guthikonda S, Alviar CL, Vaduganathan M et al (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52:743–749CrossRefPubMed
18.
Zurück zum Zitat Kienast J, Schmitz G (1990) Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 75:116–121PubMed Kienast J, Schmitz G (1990) Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 75:116–121PubMed
19.
Zurück zum Zitat Harrison P, Goodall AH (2008) “Message in the platelet”—more than just vestigial Mrna. Platelets 19:395–404CrossRefPubMed Harrison P, Goodall AH (2008) “Message in the platelet”—more than just vestigial Mrna. Platelets 19:395–404CrossRefPubMed
20.
Zurück zum Zitat Harrison P, Robinson MS, Mackie IJ, Machin SJ (1997) Reticulated platelets. Platelets 8:379–383CrossRefPubMed Harrison P, Robinson MS, Mackie IJ, Machin SJ (1997) Reticulated platelets. Platelets 8:379–383CrossRefPubMed
21.
Zurück zum Zitat Guthikonda S, Lev EI, Patel R et al (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5:490–496CrossRefPubMed Guthikonda S, Lev EI, Patel R et al (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5:490–496CrossRefPubMed
22.
Zurück zum Zitat Cesari F, Marcucci R, Gori AM et al (2013) Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI- florence 2 study. Thromb Haemost 109:846–853CrossRefPubMed Cesari F, Marcucci R, Gori AM et al (2013) Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI- florence 2 study. Thromb Haemost 109:846–853CrossRefPubMed
Metadaten
Titel
Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor
verfasst von
Alon Eisen
Hila Lerman-Shivek
Leor Perl
Eldad Rechavia
Dorit Leshem-Lev
Noa Zemer-Wassercug
Oshrat Dadush
Shirit Kazum
Pablo Codner
Ran Kornowski
Eli I. Lev
Publikationsdatum
01.07.2015
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2015
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-014-1156-4

Weitere Artikel der Ausgabe 1/2015

Journal of Thrombosis and Thrombolysis 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.